



**Australian Government**  
**Department of Health**  
**Therapeutic Goods Administration**

**TGA use only**

This form, when completed, will be classified as 'For official use only'.

For guidance on how your information will be treated by the TGA see: Treatment of information provided to the TGA at <<https://www.tga.gov.au/treatment-information-provided-tga>>.

## Special Access Scheme – Category B

### Important Information

Email completed form to [SAS@health.gov.au](mailto:SAS@health.gov.au) (preferred) or fax to 02 6232 8112.

The SAS Category B application form should be completed if guidance for use of an unapproved good will be met and the SAS Category A or SAS Category C pathways are not applicable.

### Privacy Information

For general privacy information, go to <<https://www.tga.gov.au/privacy>>.

The TGA is collecting personal information in this form in order to:

- Assess the application.
- Contact the medical practitioner and discuss the application where necessary.
- The personal information of the medical practitioner may be disclosed to State and Territory authorities with responsibility for therapeutic goods or medical practitioner registration.

### Patient details (minimum of 3 (three) identifiers required)

**Diagnosis(es) or Medical Condition(s):** Non-ketotic hyperglycinemia

**Indication:** Non-ketotic hyperglycinemia

**Clinical justification for use of product:** (e.g. Include seriousness of condition, details of previous treatment including reasons why a therapeutic good currently listed on the ARTG cannot be used for the treatment of this patient in this circumstance)

This medication conjugates glycine, a neurotransmitter, to normalise levels in plasma and CSF

### Product details (attach efficacy and safety data to support proposed use of the product and details of intended monitoring)

**Therapeutic good type**    Medicine     Biological     Medical device

| Medicine/biological   |                                    | Medical device  |                      |
|---|------------------------------------|---|----------------------|
| Trade Name (if known)   | Sponsor / Supplier                 | Trade name  |                      |
| Active ingredient(s)<br>Sodium benzoate                               |                                    | Product description (including variant <sup>2</sup> ) |                      |
| Dosage form (e.g. tablet)<br>tablet                                   | Strength (e.g., 1 mg/ml)<br>500mg  | No of units   | Sponsor / Supplier   |
| Route of administration (e.g., IV)<br>PO                              | Dose & frequency (1 tds)<br>4g tds | Proposed duration of treatment                        | Intended date of use |
| Quantity <sup>1</sup> required for treatment or duration<br>12 months |                                    |   |                      |

Treating health practitioner details

Submitter details (if different)

<sup>1</sup> The health practitioner type is any of the following: Medical practitioner; ATSI health practitioner; dentist; radiographer; nurse; midwife; occupational therapist; optometrist; pharmacist; podiatrist; psychologist.

<sup>2</sup> For substances captured by the Customs (Prohibited Imports) Regulations 1956 the quantity must be provided.

<sup>2</sup> Variant means a medical device the design of which has been varied to accommodate different patient anatomical requirements (for example, relating to the shape, size, length, diameter or gauge of the device).